H.C. Wainwright Affirms MannKind Corp (MNKD)’s ‘Buy’ Rating Buoyed by Product Pipeline

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed coverage of the stock with a ‘Buy’ rating and a $9 price target. The bullish stance is based on the company’s demonstrated strong growth of 32.5% over the last 12 months.

H.C. Wainwright Affirms MannKind Corp (MNKD)’s ‘Buy’ Rating Buoyed by Product Pipeline

Photographee.eu/Shutterstock.com

The research firm expects Tyvaso DPI to be one of the key factors driving MannKind’s valuation in the near future. Nevertheless, it maintains a cautious outlook on the Afreezza product line, expected to generate $127 million in sales by 2030.

H.C. Wainwright’s Buy rating and $9 price target are also based on expectations that MannKind’s product pipeline, including MNKD-101 and MNKD-201, will achieve 40% and 30% probability of success, respectively.

MannKind Corporation develops and commercializes inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases. Its primary product is Afrezza, an inhaled ultra-rapid-acting insulin for diabetes.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

This article is originally published at Insider Monkey.